XTLB XTL Biopharmaceuticals Ltd

NEW YORK, January 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals, Ltd. (LSE:XTL)(NASDAQ:XTLB)(TASE:XTL), a biopharmaceutical company developing drugs against hepatitis, announced today that Ron Bentsur, Chief Executive Officer, will present an overview of the Company at The Brean Murray, Carret Small Cap Institutional Investor Conference in New York City. Mr. Bentsur's presentation will take place on Wednesday, February 1, 2006 at 11:30 a.m. Eastern Time at the Grand Hyatt New York Hotel. A live audio webcast of Mr. Bentsur's presentation will be available at http://www.wsw.com/webcast/bmry2/xtl/. An archived version of the webcast will be available following the conclusion of the live presentation. Contact: Ron Bentsur, Chief Executive Officer, Tel: +1-212-531-5971 About XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd. ("XTLbio") is engaged in the research, development and commercialization of therapeutics for the treatment of infectious diseases; with a primary focus on hepatitis C. XTLbio's most advanced therapeutic in Hepatitis C is XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio's second Hepatitis C therapeutic is XTL-2125 - a small molecule inhibitor of the hepatitis C virus polymerase - expected to enter Phase 1 clinical trials in 1H2006. XTLbio hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. In addition, XTL has out-licensed to Cubist Pharmaceuticals an antibody therapeutic against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical study in transplant patients. XTLbio is publicly traded on the London, NASDAQ, and Tel-Aviv Stock Exchanges (LSE:XTL)(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT: Ron Bentsur, Chief Executive Officer, Tel: +1-212-531-5971

Copyright